Need to keep on prime of the science and politics driving biotech as we speak? Enroll to get our biotech e-newsletter in your inbox.
Hi there! Combating again a hyper 6-year-old and his 3-year-old associate in crime as I try to jot down an intro right here. My offspring say good day.
At this time, we focus on the revolutionary method a mom is trying to lift cash for a gene remedy for her baby, we see South African regulators drop their investigation into Vertex’s cystic fibrosis drug Trikafta, and extra.
The necessity-to-know this morning
Edgewise Therapeutics mentioned an experimental drug designed to forestall muscle injury achieved the first purpose of a examine involving individuals with Duchenne muscular dystrophy, a uncommon neuromuscular dysfunction. The Edgewise drug considerably diminished a blood-based biomarker for muscle loss in comparison with placebo. Muscle-function assessments confirmed enhancements, though the outcomes weren’t statistically important.
Neurocrine Biosciences received FDA approval for a drug to deal with basic congenital adrenal hyperplasia, a uncommon illness involving the adrenal glands. The drug might be marketed below the model title Crenessity.
Abbvie acquired privately held Nimble Therapeutics for $200 million. Nimble is growing medicine for autoimmune illnesses.
Because the drug business’s curiosity in gene remedy fades, one household takes an uncommon strategy
Gene remedy, in principle, may very well be harnessed to deal with every kind of uncommon illnesses. However too usually these circumstances are so uncommon that they fail to seize the curiosity of the drug business.
Amber Freed, a mom whose 7-year-old son has a uncommon genetic situation and would possibly profit from gene remedy, has provide you with a artistic answer: She hopes to lift $1 million to fund the manufacturing of a therapy in addition to early trials — and is providing to call the therapy after the highest-bidding donor.
“If we’re in a position to title the therapy after a funder, it’s really a approach to honor an individual’s title ceaselessly,” mentioned Freed, who was a monetary analyst earlier than she give up her job to chase a treatment for the ultra-rare illness Maxwell has, SLC6A1. “You’re going to be saving lives and serving to youngsters and a reputation can ceaselessly be related to grit and perseverance.”
Learn extra.
Viridian confirms advantage of drug for thyroid eye illness
An experimental therapy from Viridian Therapeutics improved the indicators and signs of continual thyroid eye illness — reaching the objectives of a second Part 3 scientific trial, the corporate reported as we speak.
Within the 15-week examine, 56% of individuals responded to therapy with Viridian’s drug, known as veligrotug, in comparison with 8% within the placebo group. Response was outlined as a significant discount in eye bulging, a trademark signal of thyroid eye illness. Listening to impairment, a carefully watched aspect impact, was reported by 13% of the individuals handled with veligrotug in comparison with 3% within the placebo arm.
In September, veligrotug, previously referred to as VRDN-001, achieved the objectives of a Part 3 examine in individuals with energetic thyroid eye illness. Viridian will embrace the outcomes of each research in its advertising and marketing software to the FDA, anticipated within the second half of 2025.
Veligrotug is an antibody that targets insulin-like development factor-1 receptor. It’s based mostly on the identical mechanism as Amgen’s Tepezza, which was accepted for thyroid eye illness in 2020 and is anticipated to generate almost $1 billion in gross sales this 12 months.
FTC declines to problem Novo-Catalent deal
Novo Holdings will finalize its $16.5 billion acquisition of the contract drug producer Catalent within the coming days, after months of scrutiny from regulators, together with the FTC.
The acquisition was prompted by sporadic shortages of one of many world’s hottest-selling medicines — Novo Nordisk’s weight reduction therapy Wegovy — and designed, partially, to unravel what has been a important and seemingly intractable drawback for Novo Nordisk.
However the prospect that Novo Holdings would possibly quickly management one of many largest gamers in pharmaceutical contract work prompted hypothesis that the FTC would object on anti-competitive grounds.
Learn extra.
South Africa: Vertex has offered enough entry to cystic fibrosis therapy
South African regulators have concluded that Vertex Prescribed drugs is providing enough entry to its cystic fibrosis therapy Trikafta. Its conclusion ends a high-profile investigation into the corporate’s dealings there — at the same time as advocacy teams insist extra must be performed.
Vertex has made Trikafta accessible through non-public well being plans and a affected person help program, however critics say that solely sufferers with premium medical protection can entry it.
Learn extra.
Extra reads
Ozempic hyperlink to uncommon imaginative and prescient loss danger confirmed in examine, Bloomberg
